Biohaven director granted 68,693 stock options
Accepted by SEC EDGAR
Learn about SEC filing dates
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Biohaven Ltd. director Robert J. Hugin received a grant of stock options, giving him the right to buy 68,693 common shares at an exercise price of $9.61 per share. These options vest in full on the earlier of April 28, 2027 or the 2027 Annual Meeting of Shareholders, subject to his continuous service. After this award, he holds 68,693 stock options directly, with an expiration date of April 28, 2036.
Insider Trade Summary
Grant/Award: 68,693 shares
Grant/Award
1 txn
Insider
HUGIN ROBERT J
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Options (Right to buy) | 68,693 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Options (Right to buy) — 68,693 options (Direct)
Holdings Before and After:
Stock Options (Right to buy), 0 to 68,693 options (Direct)
Footnotes (1)
- F1. The shares subject to this stock option will vest in full on the earlier of (a) April 28, 2027 or (b) the date of the 2027 Annual Meeting of Shareholders, in each case subject to the Reporting Person's continuous service with the Issuer through such vesting date.
Key Figures
Stock options granted: 68,693 options
Exercise price: $9.61 per share
Underlying common shares: 68,693 shares
+3 more
6 metrics
Stock options granted
68,693 options
Grant to director Robert J. Hugin on April 28, 2026
Exercise price
$9.61 per share
Conversion or exercise price for the stock options
Underlying common shares
68,693 shares
Common Shares underlying the granted stock options
Total options after grant
68,693 options
Total derivative securities following the reported transaction
Option expiration date
April 28, 2036
Expiration date of the stock options
Vesting trigger date
Earlier of April 28, 2027 or 2027 annual meeting
Vesting condition, subject to continuous service
Key Terms
Stock Options (Right to buy), exercise price, expiration date, Common Shares, +1 more
5 terms
Stock Options (Right to buy) financial
"security_title: "Stock Options (Right to buy)""
exercise price financial
"conversion_or_exercise_price: "9.6100""
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
expiration date financial
"expiration_date: "2036-04-28T00:00:00.000Z""
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
vesting financial
"will vest in full on the earlier of (a) April 28, 2027"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Biohaven (BHVN) report for Robert J. Hugin?
Biohaven reported that director Robert J. Hugin received a grant of 68,693 stock options. Each option gives him the right to buy one common share at an exercise price of $9.61, reflecting equity-based compensation rather than an open-market purchase or sale.
What are the key terms of Robert J. Hugin’s Biohaven (BHVN) stock options?
The grant covers 68,693 stock options with an exercise price of $9.61 per share and an expiration date of April 28, 2036. The options are linked to Biohaven common shares on a one-for-one basis, aligning the director’s potential gains with future share performance.
When do Robert J. Hugin’s Biohaven (BHVN) stock options vest?
The stock options will vest in full on the earlier of April 28, 2027 or the date of Biohaven’s 2027 Annual Meeting of Shareholders. Vesting is conditioned on Hugin’s continuous service with Biohaven through the applicable vesting date, according to the disclosed footnote.
How many Biohaven (BHVN) derivative securities does Robert J. Hugin hold after this grant?
Following the reported grant, Robert J. Hugin holds 68,693 stock options directly. Each option is a right to buy one Biohaven common share at $9.61 before expiration on April 28, 2036, indicating his entire reported derivative position in this filing.
Does the Biohaven (BHVN) Form 4 show a market sale or purchase by Robert J. Hugin?
The Form 4 shows a grant of 68,693 stock options classified as an acquisition under code A. This represents an award of derivative securities as compensation, not an open-market buy or sell of existing Biohaven common shares by the director.
AI-generated analysis. How Rhea-AI works. Not financial advice.
